Crohn's Disease FDA approvals, PDUFA dates and pipeline.
Updated Snapshot 20261116T112050ZBuilt
We track 18 Crohn's Disease drugs. No FDA approvals recorded yet.
Drugs
| Drug | Sponsor | Modality | Designations |
|---|---|---|---|
| ABBV-8736 | ABBV | — | — |
| AZD7798 | AZN | — | — |
| brivekimig (SAR442970) | SNY | — | — |
| darvadstrocel (CX601) | TAK | — | — |
| duvakitug (TEV-48574) | SNY | — | — |
| Tremfya (guselkumab) | JNJ | biologic | Priority Review |
| iv tulisokibart (PRA023) | MRK | — | — |
| mirikizumab (LY3074828) | LLY | — | — |
| obefazimod (ABX464) | ABVX | — | — |
| Skyrizi® (risankizumab) | ABBV | antibody | — |
| risankizumab iv (ABBV-066) | ABBV | — | — |
| risankizumab sc (ABBV-066) | ABBV | — | — |
| SAR441566 | SNY | — | — |
| SL-325 | STTK | — | — |
| Zepbound (tirzepatide) | LLY | peptide | Priority Review |
| Entyvio® (vedolizumab) | TAK | antibody | — |
| vedolizumab iv (MLN0002) | TAK | — | — |
| zasocitinib (TAK-279) | TAK | small_molecule | Priority Review |
Upcoming catalysts
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Aug to Nov 2026Quarter disclosed | AZD7798 | AZN | Topline readout | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| Dec 2026 to Mar 2027Quarter disclosed | brivekimig (SAR442970) | SNY | Topline readout | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| December 2026Month disclosed | brivekimig (SAR442970) | SNY | Primary completion | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| Feb to May 2027Quarter disclosed | zasocitinib (TAK-279) | TAK | Topline readout | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| February 2027Month disclosed | zasocitinib (TAK-279) | TAK | Primary completion | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| March 2027Month disclosed | risankizumab sc (ABBV-066) | ABBV | Primary completion | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2027Quarter disclosed | risankizumab sc (ABBV-066) | ABBV | Topline readout | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| Jun to Sep 2027Quarter disclosed | Tremfya (guselkumab) | JNJ | Topline readout | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| Jun to Sep 2027Quarter disclosed | Entyvio® (vedolizumab) | TAK | Topline readout | Crohn's Disease | Scheduled | sec_424b |
| June 2027Month disclosed | Tremfya (guselkumab) | JNJ | Primary completion | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| June 2027Month disclosed | Entyvio® (vedolizumab) | TAK | Primary completion | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| September 2027Month disclosed | RINVOQ® (upadacitinib) | ABBV | Primary completion | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2027Quarter disclosed | RINVOQ® (upadacitinib) | ABBV | Topline readout | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| Oct 2027 to Jan 2028Quarter disclosed | Tremfya (guselkumab) | JNJ | Topline readout | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| October 2027Month disclosed | Tremfya (guselkumab) | JNJ | Primary completion | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| December 2027Month disclosed | mirikizumab (LY3074828) | LLY | Primary completion | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| Dec 2027 to Mar 2028Quarter disclosed | mirikizumab (LY3074828) | LLY | Topline readout | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2028Quarter disclosed | zasocitinib (TAK-279) | TAK | Topline readout | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| March 2028Month disclosed | zasocitinib (TAK-279) | TAK | Primary completion | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| July 2028Month disclosed | SL-325 | STTK | Primary completion | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| Jul to Oct 2028Quarter disclosed | SL-325 | STTK | Topline readout | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| Oct 2028 to Jan 2029Quarter disclosed | iv tulisokibart (PRA023) | MRK | Topline readout | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| October 2028Month disclosed | iv tulisokibart (PRA023) | MRK | Primary completion | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| February 2029Month disclosed | risankizumab iv (ABBV-066) | ABBV | Primary completion | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| Feb to May 2029Quarter disclosed | risankizumab iv (ABBV-066) | ABBV | Topline readout | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| April 2029Month disclosed | Skyrizi® (risankizumab) | ABBV | Primary completion | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| Apr to Jul 2029Quarter disclosed | Skyrizi® (risankizumab) | ABBV | Topline readout | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| May to Aug 2029Quarter disclosed | duvakitug (TEV-48574) | SNY | Topline readout | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| May 2029Month disclosed | duvakitug (TEV-48574) | SNY | Primary completion | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| Aug to Nov 2029Quarter disclosed | duvakitug (TEV-48574) | SNY | Topline readout | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| August 2029Month disclosed | duvakitug (TEV-48574) | SNY | Primary completion | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| January 2030Month disclosed | ABBV-8736 | ABBV | Primary completion | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| Jan to Apr 2030Quarter disclosed | ABBV-8736 | ABBV | Topline readout | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2030Quarter disclosed | vedolizumab iv (MLN0002) | TAK | Topline readout | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| March 2030Month disclosed | vedolizumab iv (MLN0002) | TAK | Primary completion | Crohn's Disease | Scheduled | ClinicalTrials.gov |
Past catalysts and decisions
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| August 10, 2026 | AZD7798 | AZN | Primary completion | Crohn's Disease | Completed | ClinicalTrials.gov |
| July 30, 2026 | SAR441566 | SNY | Primary completion | Crohn's Disease | Withdrawn | ClinicalTrials.gov |
| May 23, 2025 | Tremfya (guselkumab) | JNJ | Primary completion | Crohn's Disease | Completed | ClinicalTrials.gov |
| Oct 2024Month disclosed | obefazimod (ABX464) | ABVX | Trial start | Crohn's disease | Completed | sec_424b |
All indications · Approval rates by indication
Questions
What Crohn's Disease drugs have upcoming PDUFA dates?
None disclosed.
Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.